Investment
Features
FeesSafety
Academy
More
Pluang+

Ethereum's Glamsterdam upgrade to activate on Sepolia testnet Oct 6 amid caution over testnet attack risks

Protocol Fundamentals
18 Sep 2026
TheNewsCrypto
View Source
Neutral
Ethereum's Glamsterdam upgrade to activate on Sepolia testnet Oct 6 amid caution over testnet attack risks

Ethereum developers announced that the Glamsterdam upgrade will activate on the Sepolia testnet on October 6. This upgrade involves enshrined proposer-builder separation (ePBS), which separates block building from validator consensus to improve network security. Developers warn that the low-cost test ether on Sepolia could be exploited by malicious actors creating many disposable builder identities to disrupt testing by withholding execution payloads. The Sepolia test follows a successful controlled Devnet-11 test, with further adversarial testing planned before the mainnet rollout, currently targeted for late 2026 but with no fixed date yet.

Ethereum's Glamsterdam testnet upgrade is in focus, with Pluang market data providing context as of Sep 18, 2026 19:01 WIB: Among 50 major cryptocurrencies priced on Pluang, 46 rose and 3 fell today. Notable movers include UNI (Uniswap) at Rp154.873 with a 27.81% increase and a typical hold time of 65 days, THETA (Theta Network) at Rp3.677 up 15.16% with a 77-day hold time, and COTI at Rp380 rising 12.29% with a 121-day hold time.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
2 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
3 hours ago
India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

India's gold demand stays strong despite price swings; ETF inflows and futures trading rise in August.

In August, India's gold market showed resilience with steady jewelry buying and physical investment demand despite volatile gold prices. Domestic gold prices rose 12% in August but pulled back in September amid changing Fed policy expectations. Gold ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App